retatrutide clinical trials retatrutide mechanism First phase 3 data, a Triumph of Science! Perceived benefits of treatment for

Giving exogenous GLP-1 analogues or increasing endogenous GLP-1 levels can enhance the signaling of GLP-1R, and the activation of GLP-1R can effectively inhibit glucagon secretion in human body

Watch in 10 minutes or less

A 2021 study published in Nature Communications showed that exogenous MOTS-C treatment enhanced physical performance in mice across all age groups young, middle-aged, and old

There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease #osteoarthritis NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs

BMJ Open Gastroenterology

That structural problem requires treatment